Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3331866 | Hematology/Oncology Clinics of North America | 2007 | 41 Pages |
Abstract
Studies of bortezomib, thalidomide, and lenalidomide have shown promising clinical activity in relapsed/refractory multiple myeloma (MM). Bortezomib alone and in combination with other agents is associated with high response rates, consistently high rates of complete response, and a predictable and manageable profile of adverse events. Thalidomide-based regimens have also shown substantial clinical activity. The accumulating experience from ongoing trials of bortezomib/lenalidomide/dexamethasone combinations in patients who have relapsed/refractory or newly diagnosed MM will provide critical information that will determine the possible role of this combination as the basic backbone for combination regimens for management of advanced MM.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Efstathios Kastritis, Constantine S. Mitsiades, Meletios A. Dimopoulos, Paul G. Richardson,